Top

European Journal of Medical Research

Published in:

Open Access 01-12-2024 | Kidney Cancer | Research

Single-cell combined bioinformatics analysis: construction of immune cluster and risk prognostic model in kidney renal clear cells based on CD8⁺ T cell-associated genes

Authors: Haifeng Gao, Hang Sun, Aifeng He, Hui Liu, Zihang Zhang, Dongling Li, Weipu Mao, Jinke Qian

Published in: European Journal of Medical Research | Issue 1/2024

Abstract

Background

Kidney cancer is an immunogenic solid tumor, characterized by high tumor burden and infiltration of CD8⁺ T cells. Although immunotherapy targeting the PD1/CTLA-4 axis has demonstrated excellent clinical efficacy, clinical outcomes in most patients are poor.

Methods

We used the RNA sequencing data from the GEO database for KIRC GSE121636 and normal kidney tissue GSE131685, and performed single-cell analysis for cluster identification, pathway enrichment, and CD8⁺ T cell-associated gene identification. Subsequently, the significance of different CD8⁺ T-cell associated gene subtypes was elucidated by consensus clustering, pathway analysis, mutated gene analysis, and KIRC immune microenvironment analysis in the TCGA–KIRC disease cohort. Single gene analysis identified LAG3 as the most critical CD8⁺ T-cell-associated gene and its function was verified by cell phenotype and immunohistochemistry in KIRC.

Results

In the present study, CD8⁺ T-cell associated genes in KIRC were screened, including GZMK, CD27, CCL4L2, FXYD2, LAG3, RGS1, CST7, DUSP4, CD8A, and TRBV20-1 and an immunological risk prognostic model was constructed (risk score = − 0.291858656434841*GZMK − 0.192758342489394*FXYD2 + 0.625023643446193*LAG3 + 0.161324477181591*RGS1 − 0.380169045328895*DUSP4 − 0.107221347575037*TRBV20-1). LAG3 was identified and proved as the most critical CD8⁺ T cell-associated gene in KIRC.

Conclusion

We proposed and constructed an immunological risk prognostic model for CD8⁺ T cell-associated genes and identified LAG3 as a pivotal gene for KIRC progression and CD8⁺ T-cell infiltration. The model comprehensively explained the immune microenvironment and provided novel immune-related therapeutic targets and biomarkers in KIRC.

Available only for authorised users

Ricketts CJ, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:3698. https://doi.org/10.1016/j.celrep.2018.06.032.CrossRefPubMed

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029.CrossRefPubMed

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Ljungberg B, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–21. https://doi.org/10.1016/j.eururo.2011.06.049.CrossRefPubMed

Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008;15:3954–66.PubMed

Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721–35. https://doi.org/10.1038/s41581-020-0316-3.CrossRefPubMed

Coppin C, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005. https://doi.org/10.1002/14651858.CD001425.pub2.CrossRefPubMed

Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42:539–48. https://doi.org/10.1053/j.seminoncol.2015.05.015.CrossRefPubMedPubMedCentral

Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. https://doi.org/10.1056/NEJMoa1200690.CrossRefPubMedPubMedCentral

10.

Nakano O, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61:5132–6.PubMed

11.

Giraldo NA, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031–40. https://doi.org/10.1158/1078-0432.CCR-14-2926.CrossRefPubMed

12.

Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298–312. https://doi.org/10.1038/s41568-021-00339-z.CrossRefPubMed

13.

Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509–21. https://doi.org/10.1002/jcp.27782.CrossRefPubMed

14.

van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20:218–32. https://doi.org/10.1038/s41568-019-0235-4.CrossRefPubMedPubMedCentral

15.

Drake CG, Stein MN. The immunobiology of kidney cancer. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.79.2648.CrossRefPubMed

16.

Verma V, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231–43. https://doi.org/10.1038/s41590-019-0441-y.CrossRefPubMedPubMedCentral

17.

Pauken KE, et al. The PD-1 pathway regulates development and function of memory CD8(+) T cells following respiratory viral infection. Cell Rep. 2020;31: 107827. https://doi.org/10.1016/j.celrep.2020.107827.CrossRefPubMedPubMedCentral

18.

Borcherding N, et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun Biol. 2021;4:122. https://doi.org/10.1038/s42003-020-01625-6.CrossRefPubMedPubMedCentral

19.

Liao J, et al. Single-cell RNA sequencing of human kidney. Sci Data. 2020;7:4. https://doi.org/10.1038/s41597-019-0351-8.CrossRefPubMedPubMedCentral

20.

Wilkerson MD, Hayes DN. Consensus cluster plus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572–3. https://doi.org/10.1093/bioinformatics/btq170.CrossRefPubMedPubMedCentral

21.

Danaher P, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18. https://doi.org/10.1186/s40425-017-0215-8.CrossRefPubMedPubMedCentral

22.

Bukavina L, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529–42. https://doi.org/10.1016/j.eururo.2022.08.019.CrossRefPubMed

23.

Motzer RJ, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15. https://doi.org/10.1056/NEJMoa1816047.CrossRefPubMedPubMedCentral

24.

Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27. https://doi.org/10.1056/NEJMoa1816714.CrossRefPubMed

25.

Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90. https://doi.org/10.1056/NEJMoa1712126.CrossRefPubMedPubMedCentral

26.

Rini BI, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393:2404–15. https://doi.org/10.1016/S0140-6736(19)30723-8.CrossRefPubMed

27.

Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34. https://doi.org/10.1038/nrclinonc.2017.101.CrossRefPubMed

28.

Zajac AJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205–13. https://doi.org/10.1084/jem.188.12.2205.CrossRefPubMedPubMedCentral

29.

Huang Y, Jia A, Wang Y, Liu G. CD8(+) T cell exhaustion in anti-tumor immunity: the new insights for cancer immunotherapy. Immunology. 2022. https://doi.org/10.1111/imm.13588.CrossRefPubMedPubMedCentral

30.

Pignon JC, et al. irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial. Clin Cancer Res. 2019;25:2174–84. https://doi.org/10.1158/1078-0432.CCR-18-3206.CrossRefPubMedPubMedCentral

31.

Jansen CS, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465–70. https://doi.org/10.1038/s41586-019-1836-5.CrossRefPubMedPubMedCentral

32.

Giraldo NA, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23:4416–28. https://doi.org/10.1158/1078-0432.CCR-16-2848.CrossRefPubMed

33.

Miao D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359:801–6. https://doi.org/10.1126/science.aan5951.CrossRefPubMedPubMedCentral

34.

Beckermann K, et al. Targeting metabolic dysregulation of T cells in kidney cancer. J Clinical Oncol. 2020. https://doi.org/10.1200/JCO.2020.38.6_suppl.722.CrossRef

35.

Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17:245–61. https://doi.org/10.1038/s41581-020-00359-2.CrossRefPubMed

36.

Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.CrossRef

37.

Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol. 2011;344:269–78. https://doi.org/10.1007/82_2010_114.CrossRefPubMedPubMedCentral

38.

Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–9. https://doi.org/10.1038/ni.2035.CrossRefPubMed

39.

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82. https://doi.org/10.1200/JCO.2014.59.4358.CrossRefPubMedPubMedCentral

40.

Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80–96. https://doi.org/10.1111/imr.12519.CrossRefPubMedPubMedCentral

41.

Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15:6225–31. https://doi.org/10.1158/1078-0432.CCR-09-0068.CrossRefPubMed

42.

Ferro M, et al. Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review. Ther Adv Urol. 2023;15:17562872231164804. https://doi.org/10.1177/17562872231164803.CrossRefPubMedPubMedCentral

43.

Ferro M, et al. Radiogenomics in renal cancer managemen—current evidence and future prospects. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24054615.CrossRefPubMedPubMedCentral

44.

Ascione CM, et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115: 102530. https://doi.org/10.1016/j.ctrv.2023.102530.CrossRefPubMed

Title: Single-cell combined bioinformatics analysis: construction of immune cluster and risk prognostic model in kidney renal clear cells based on CD8+ T cell-associated genes
Authors: Haifeng Gao
Hang Sun
Aifeng He
Hui Liu
Zihang Zhang
Dongling Li
Weipu Mao
Jinke Qian
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: European Journal of Medical Research / Issue 1/2024
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-024-01689-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Single-cell combined bioinformatics analysis: construction of immune cluster and risk prognostic model in kidney renal clear cells based on CD8⁺ T cell-associated genes

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Association of triglyceride glucose index with cardiovascular events: insights from the Isfahan Cohort Study (ICS)

Network pharmacology and molecular docking analysis on Shenfu Qiangxin indicate mTOR is a potential target to treat heart failure

Predictive modeling for acute kidney injury after percutaneous coronary intervention in patients with acute coronary syndrome: a machine learning approach

Threshold-modifying effect of the systemic inflammatory response index on kidney function decline in hypertensive patients

Metabolomic profiling of exosomes reveals age-related changes in ovarian follicular fluid

TR4 worsen urosepsis by regulating GSDMD